Overview
To investigate the dose response in respect of weight decrease following repeated oral administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with volume overload despite having received diuretics other than vasopressin antagonists
Eligibility
Inclusion Criteria:
- Subjects with CHF with lower limb edema, pulmonary congestion, or jugular venous distension due to volume overload.
- Subjects undergoing any of the following diuretic therapies
- Loop diuretics at a dosage equivalent to 40 mg/day or more of furosemide tablet/fine granule
- Concomitant administration of a loop diuretic and a thiazide diuretic (including similar drugs) at any doses
- Concomitant administration of a loop diuretic and a mineralocorticoid receptor antagonist or potassium-sparing diuretic at any doses
- Subjects who were currently hospitalized or who are able to be hospitalized
Exclusion Criteria:
- Subjects with acute heart failure
- Subjects with an assisted circulation device
- Subjects who cannot sense thirst or who have difficulty in ingesting water